Business

Announcement Published in a Journal Regarding Voluntary Disclosure of Phase II Study on the Safety, Tolerability and Preliminary Efficacy of Polyethylene Glycol Irinotecan as Second-Line Monotherapy for Small Cell Lung Cancer

Announcement Published in a Journal Regarding Voluntary Disclosure of Phase II Study on the Safety, Tolerability and Preliminary Efficacy of Polyethylene Glycol Irinotecan as Second-Line Monotherapy for Small Cell Lung Cancer

articleJenkem Technology Co., Ltd. Class ASeptember 4, 20245/news/announcement-published-in-a-journal-regarding-voluntary-disclosure-of-phase-ii-study-on-the-safety-tolerability-and-preliminary-efficacy-of-polyethylene-glycol-irinotecan-as-second-line-monotherapy-for-small-cell-lung-cancer
Announcement Published in a Journal Regarding Voluntary Disclosure of Phase II Study on the Safety, Tolerability and Preliminary Efficacy of Polyethylene Glycol Irinotecan as Second-Line Monotherapy for Small Cell Lung Cancer

About this update from Jenkem Technology Co., Ltd. Class A

Announcement Published in a Journal Regarding Voluntary Disclosure of Phase II Study on the Safety, Tolerability and Preliminary Efficacy of Polyethylene Glycol Irinotecan as Second-Line Monotherapy for Small Cell Lung CancerThe abstract is for reference only. Please refer to the full text of the announcement on the very day.Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Jenkem Technology Co., Ltd. Class A